We use our own first-party analytics to understand and improve the site (we never sell your data). You can also allow advertising cookies for personalized marketing, or decline them.

Nox Amino
Research-grade peptides. Third-party tested and verified.

BPC-157 vs TB-500: What the Recovery Research Shows

Research summary. BPC-157 and TB-500 are two distinct research peptides often discussed together in tissue-repair literature. BPC-157 is a 15-amino-acid sequence derived from a gastric protein, studied preclinically via FAK-paxillin signaling; TB-500 is a 7-amino-acid fragment of thymosin beta-4, an actin-sequestering peptide. Published work on both is overwhelmingly preclinical.

Author: Nox Amino Research Team Reviewed by: the Nox Amino Research Team Published: June 30, 2026 · Updated: June 30, 2026 Editorial methodology: /learn/editorial-standards

Research Use Only (RUO). All materials referenced on this page are intended exclusively for laboratory research and analytical use. They are not drugs, dietary supplements, or articles for human or veterinary consumption, and nothing here constitutes medical advice, a therapeutic claim, or a recommendation for use in or on the body. Statements below describe published third-party studies in their own terms; they are not claims about outcomes for any reader. See our Certificates of Analysis for identity and purity data on stocked reference materials.

How BPC-157 and TB-500 are classified

Within published literature, BPC-157 and TB-500 are distinguished primarily by peptide origin and mechanism: where each sequence comes from and how it is described to act at the cellular level. This is a structural and mechanistic classification, independent of any individual's experience, and the basis on which the two compounds are most often compared in research discussions.

BPC-157 is described in the literature as a stable gastric pentadecapeptide: a 15-amino-acid sequence said to be derived from a protein found in gastric juice. In a 2011 report in the Journal of Applied Physiology, Chang and colleagues characterized BPC 157 and reported its effects on cultured tendon fibroblasts, including accelerated explant outgrowth and increased in-vitro cell migration (Chang et al., J Appl Physiol 2011; PMID 21030672). Across this body of work, BPC-157 is consistently framed as a synthetic peptide studied in animal and cell-culture injury models.

TB-500 is described as a synthetic fragment of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid actin-sequestering peptide. TB-500 itself corresponds to a shorter 7-residue sequence (often written LKKTETQ) drawn from the actin-binding region of the full protein. In a 2004 report in Nature, Bock-Marquette and colleagues characterized thymosin beta-4 as a "G-actin sequestering peptide" and described its effects on cell migration and survival in a cardiac model (Bock-Marquette et al., Nature 2004; PMID 15565145). Because TB-500 is studied as a fragment of this larger molecule, much of the relevant mechanism literature concerns thymosin beta-4 directly.

The phrase "wolverine peptide" is an informal nickname that has circulated online in reference to these repair-associated research compounds. It is not a scientific term, a research code, or a regulatory designation; the relevant identifiers remain the molecules themselves: BPC-157 and TB-500 (thymosin beta-4 fragment).

Comparison table: research compound profiles

The table below summarizes how the published literature classifies each compound. It describes research status and mechanism, not outcomes for any reader, and contains no dosing or therapeutic guidance.

Attribute (per literature)BPC-157TB-500
Common identifierBPC-157 (pentadecapeptide)TB-500 (thymosin beta-4 fragment)
Described originSequence derived from a gastric-juice proteinSynthetic fragment of thymosin beta-4 (Tβ4)
Amino-acid length15 residues7 residues (fragment); Tβ4 full length is 43
Described mechanism (literature)Tendon-fibroblast outgrowth, survival, migration via FAK-paxillinG-actin sequestration; cell migration and survival
Representative published studyChang et al., J Appl Physiol 2011Bock-Marquette et al. (Tβ4), Nature 2004
Study referencePMID 21030672 · PMID 16583442PMID 15565145 · PMID 10469335
Reported research stage (literature)Predominantly preclinical; human evidence very limitedPredominantly preclinical

Table reflects how third-party publications describe these compounds. It is not a statement of comparative effectiveness, safety, or suitability for any use in humans.

What the mechanism difference means in research terms

The most cited distinction between these two compounds is the pathway each is associated with in published descriptions. BPC-157 is frequently discussed in the context of connective-tissue cell behavior: in the 2011 Journal of Applied Physiology report, Chang and colleagues found that BPC 157 increased phosphorylation of FAK and paxillin in a dose-dependent manner and concluded that it promoted tendon-fibroblast outgrowth, survival under oxidative stress, and migration through that signaling pathway (PMID 21030672). A separate rat Achilles-detachment study by Krivic and colleagues described improved tendon-to-bone healing markers and more organized collagen in treated animals (Krivic et al., J Orthop Res 2006; PMID 16583442).

TB-500, by contrast, is studied through the lens of actin biology. Thymosin beta-4 binds monomeric G-actin and is described as influencing cell migration; the 2004 Nature report linked it to integrin-linked kinase and Akt signaling in a cardiac-injury model (PMID 15565145). An earlier 1999 study by Malinda and colleagues reported that thymosin beta-4 increased re-epithelialization and stimulated keratinocyte migration in a rat full-thickness wound model (Malinda et al., J Invest Dermatol 1999; PMID 10469335). These are descriptions of findings in animal and cell-culture systems, not statements about effects in any person.

A 2025 systematic review of BPC-157 in orthopaedic sports medicine underscores the evidence stage for at least one of these compounds: across 36 studies, the authors noted that the literature was almost entirely preclinical and reported that no clinical safety data were found (Vasireddi et al., HSS J 2025; PMID 40756949). For laboratory work, both BPC-157 and TB-500 are best understood as reference materials characterized by identity and purity rather than by any human outcome.

How researchers characterize these reference materials

For in-vitro and analytical protocols, the attributes that matter are identity (e.g., by mass spectrometry) and purity (e.g., by HPLC): the data documented on a Certificate of Analysis. These analytical attributes, not human outcomes, are the appropriate basis for selecting a research peptide and for comparing one batch or supplier to another. You can review available COA data on our /coas page. For broader background on how we describe research compounds, see our /faq.

Sourcing COA-verified research compounds

Nox Amino stocks research-grade reference materials with batch-specific Certificates of Analysis. To view COA-verified BPC-157, see the product page at /shop/bpc157; TB-500 is stocked as the BPC-157 + TB-500 blend at /shop/bpc157-tb500. Or browse the full catalog at /shop.

Create a free account to view COA-verified BPC-157 and TB-500, access batch-specific analytical data, and see member pricing. → Create your account

This article cites third-party research for informational and laboratory-research purposes only. Nox Amino sells research compounds intended for laboratory and analytical use only, not for human or animal consumption. Nothing on this page is medical advice or a therapeutic claim. Editorial methodology and review process: /learn/editorial-standards.

FAQ (for FAQPage schema)

Q: What is the difference between BPC-157 and TB-500 as research compounds?

Published literature distinguishes them by origin and mechanism. BPC-157 is described as a 15-amino-acid pentadecapeptide derived from a gastric-juice protein, studied via FAK-paxillin signaling in tendon fibroblasts (Chang et al., J Appl Physiol 2011, PMID 21030672). TB-500 is described as a 7-amino-acid fragment of the actin-sequestering peptide thymosin beta-4 (Bock-Marquette et al., Nature 2004, PMID 15565145). Both are reference materials for laboratory research use only.

Q: Why are BPC-157 and TB-500 called the "wolverine peptide"?

"Wolverine peptide" is an informal online nickname sometimes applied to repair-associated research compounds; it is not a scientific term, research code, or regulatory designation. In the published literature the compounds are identified as BPC-157 and TB-500 (a thymosin beta-4 fragment). The molecule name, not any nickname, is the relevant identifier for a research material.

Q: What research stage are BPC-157 and TB-500 at?

According to published reports, the literature on both compounds is predominantly preclinical: animal and cell-culture models. A 2025 systematic review of BPC-157 in orthopaedic sports medicine reported that across 36 studies the evidence was almost entirely preclinical and that no clinical safety data were found (Vasireddi et al., HSS J 2025, PMID 40756949). These references describe study status only and are not statements about use in humans.

Q: What does "actin-sequestering" mean for TB-500?

In the published literature, thymosin beta-4 (the parent molecule of TB-500) is described as a "G-actin sequestering peptide," meaning it binds monomeric actin, a property linked in research to cell migration (Bock-Marquette et al., Nature 2004, PMID 15565145). This is a mechanistic and structural classification of the compound studied in laboratory models, not a claim about any effect in a person.

Q: How do I verify the identity and purity of a research peptide like BPC-157 or TB-500?

Identity and purity are documented on a batch-specific Certificate of Analysis (COA), typically using methods such as mass spectrometry for identity and HPLC for purity. These analytical attributes, not human outcomes, are the appropriate basis for selecting a research compound. You can review available COA data on the /coas page, and create a free account to access batch-specific analytical data and member pricing.

Sources

Frequently Asked Questions

What is the difference between BPC-157 and TB-500 as research compounds?

Published literature distinguishes them by origin and mechanism. BPC-157 is described as a 15-amino-acid pentadecapeptide derived from a gastric-juice protein, studied via FAK-paxillin signaling in tendon fibroblasts (Chang et al., J Appl Physiol 2011, PMID 21030672). TB-500 is described as a 7-amino-acid fragment of the actin-sequestering peptide thymosin beta-4 (Bock-Marquette et al., Nature 2004, PMID 15565145). Both are reference materials for laboratory research use only.

Why are BPC-157 and TB-500 called the "wolverine peptide"?

"Wolverine peptide" is an informal online nickname sometimes applied to repair-associated research compounds; it is not a scientific term, research code, or regulatory designation. In the published literature the compounds are identified as BPC-157 and TB-500 (a thymosin beta-4 fragment). The molecule name, not any nickname, is the relevant identifier for a research material.

What research stage are BPC-157 and TB-500 at?

According to published reports, the literature on both compounds is predominantly preclinical: animal and cell-culture models. A 2025 systematic review of BPC-157 in orthopaedic sports medicine reported that across 36 studies the evidence was almost entirely preclinical and that no clinical safety data were found (Vasireddi et al., HSS J 2025, PMID 40756949). These references describe study status only and are not statements about use in humans.

What does "actin-sequestering" mean for TB-500?

In the published literature, thymosin beta-4 (the parent molecule of TB-500) is described as a "G-actin sequestering peptide," meaning it binds monomeric actin, a property linked in research to cell migration (Bock-Marquette et al., Nature 2004, PMID 15565145). This is a mechanistic and structural classification of the compound studied in laboratory models, not a claim about any effect in a person.

How do I verify the identity and purity of a research peptide like BPC-157 or TB-500?

Identity and purity are documented on a batch-specific Certificate of Analysis (COA), typically using methods such as mass spectrometry for identity and HPLC for purity. These analytical attributes, not human outcomes, are the appropriate basis for selecting a research compound. You can review available COA data on the /coas page, and create a free account to access batch-specific analytical data and member pricing.

References